Sharemaestro company-news research for BeiGene, Ltd. (ONC), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ONC news and sentiment
BeiGene, Ltd.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone65/100
โ
Published 30-day score51/100
Latest source headline
Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $420
Moomoo ยท 09 Oct 2026 05:42
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
6 current stories are mapped specifically to ONC.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.075.
Confidence is 18/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
18/100
Confidencethin evidence
95%/100
Company news6 company stories
88/100
Story agreement12/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.075 after freshness weightingSource breadth60
3 independent publishersCompany relevance95
share tied directly to this companyFreshness18
recency-weighted evidenceAgreement88
how closely stories agreePublisher mix48
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202653USD 354.47-1.0%
02 Oct 202652USD 358.07-0.8%
25 Sep 202651USD 360.85+2.9%
18 Sep 202654USD 350.84+1.2%
11 Sep 202659USD 346.51-3.3%
04 Sep 202662USD 358.26-2.3%
28 Aug 202662USD 366.73-2.1%
21 Aug 202655USD 374.47+7.8%
Provisional evidence
News subjects
What is shaping the score
Analyst action732 stories ยท 33%
Market update412 stories ยท 33%
Earnings601 stories ยท 17%
Balance sheet411 stories ยท 17%
Source mix
Where the evidence comes from
Moomoo723 stories ยท 50%
AD HOC NEWS412 stories ยท 33%
Simply Wall Street601 stories ยท 17%
Recurring subjects
Subjects appearing most often
Life Sciences6Financial Markets5Earnings3Finance1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral11 Oct 18:12
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 18:12 | 52 | -1 | 23/100 (-4) | 6 (-2) | Provisional |
| 09 Oct 23:59 | 53 | +0 | 27/100 (-2) | 8 (-3) | Provisional |
| 01 Oct 23:59 | 53 | +1 | 29/100 (+2) | 11 (-2) | Provisional |
| 26 Sep 23:59 | 52 | +0 | 27/100 (+1) | 13 (-5) | Provisional |
| 23 Sep 23:59 | 52 | +0 | 26/100 (-1) | 18 (+1) | Provisional |
| 20 Sep 23:59 | 52 | -7 | 27/100 (-5) | 17 (-5) | Provisional |
| 11 Sep 23:59 | 59 | +3 | 32/100 (+4) | 22 (-2) | Provisional |
| 10 Sep 23:59 | 56 | -5 | 28/100 (-4) | 24 (-5) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 6 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious โ 0 โ Constructive
Analyst action2 stories
0.0%67.9%
Balance sheet1 story
16.8%0.0%
Earnings1 story
0.0%14.4%
Market update2 stories
0.9%0.0%
Each side uses the same scale: 0โ67.9% of the retained directional evidence.
Where the influence comes from
68.8%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
72/100 tone
Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a price target of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
58.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a price target of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
- Published
- 09 Oct 2026 05:42
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 53/100
- 30-day weight
- 58.7% of directional evidence ยท 7.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
77/100 tone
J.P. Morgan has reiterated its Buy rating for BeiGene (ONC.US) and increased its target price to $445. This positive adjustment by the investment bank reflects continued confidence in the biopharmaceutical company's financial outlook and growth prospects.
8.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
J.P. Morgan has reiterated its Buy rating for BeiGene (ONC.US) and increased its target price to $445. This positive adjustment by the investment bank reflects continued confidence in the biopharmaceutical company's financial outlook and growth prospects.
- Published
- 01 Oct 2026 16:27
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Shared story ยท 78%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 50/100
- 30-day weight
- 8.9% of directional evidence ยท 14.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
40/100 tone
A director at BeiGene (ONC.US) has sold 68,000 shares of common stock for a total of US$11.32 million. This transaction occurred at an average price of US$166.45 per share.
0.9% of directional evidence
Low story strength
Scoring detailsDirect company coverage
A director at BeiGene (ONC.US) has sold 68,000 shares of common stock for a total of US$11.32 million. This transaction occurred at an average price of US$166.45 per share.
- Published
- 01 Oct 2026 00:02
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Low ยท 34/100
- 30-day weight
- 0.9% of directional evidence ยท 15.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
60/100 tone
BeOne Medicines (ONC) has garnered attention following its rebrand from BeiGene, Ltd. in May 2025, maintaining a strong oncology focus. While the company's strong revenue growth and a fair value of $433.02 suggest it is undervalued by 17%, its high P/E ratio of 62.6x, compared to an indusโฆ
14.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BeOne Medicines (ONC) has garnered attention following its rebrand from BeiGene, Ltd. in May 2025, maintaining a strong oncology focus. While the company's strong revenue growth and a fair value of $433.02 suggest it is undervalued by 17%, its high P/E ratio of 62.6x, compared to an industry average of 17.3x, indicates potential valuation risk. The article highlights both the optimistic growth narrative driven by its best-in-class oncology therapies and the risks associated with competition and drug pricing pressures.
- Published
- 26 Sep 2026 15:50
- News subject
- Earnings
- Why this score
- Operating growth, Positive valuation view
- Company focus
- Shared story ยท 78%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 36/100
- 30-day weight
- 14.5% of directional evidence ยท 19.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
59/100 tone
Market update
BeiGene stock gains 2.16 percent as biotech shares rise
BeiGene stock increased by 2.16 percent in Hong Kong trading on September 22, 2026, as the broader biotechnology sector also saw gains. While this reflects a positive market signal, the article emphasizes that the company's financial performance and operating figures remain the critical mโฆ
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BeiGene stock increased by 2.16 percent in Hong Kong trading on September 22, 2026, as the broader biotechnology sector also saw gains. While this reflects a positive market signal, the article emphasizes that the company's financial performance and operating figures remain the critical metrics for investors to assess its valuation, rather than relying solely on sector-driven movements. The gain was noted to be smaller than some other biotech advances on the same day, suggesting a sector-wide uplift rather than a company-specific event.
- Published
- 23 Sep 2026 00:19
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Low ยท 31/100
- 30-day weight
- <0.1% of directional evidence ยท 23.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
41/100 tone
BeiGene Ltd. (BGNE) stock is holding steady despite recent quarterly losses, as investors weigh the company's expanding oncology pipeline against its ongoing cash burn. While revenue continues to grow, operating expenses keep the company in the red, underscoring the long path to profitabiโฆ
17% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BeiGene Ltd. (BGNE) stock is holding steady despite recent quarterly losses, as investors weigh the company's expanding oncology pipeline against its ongoing cash burn. While revenue continues to grow, operating expenses keep the company in the red, underscoring the long path to profitability. Analysts focus on pipeline strength and global partnerships, but also highlight the need for continued funding and the risks associated with clinical development and commercialization.
- Published
- 20 Sep 2026 13:03
- News subject
- Balance sheet
- Why this score
- Negative financial language
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 38/100
- 30-day weight
- 17% of directional evidence ยท 26.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
Earlier company news
ONC news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
07Aug 2026
ArchivedPositive tone
BeOne Medicines (ONC) Stock Climbs As Profit Growth Meets BRUKINSA Reliance
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The โฆ
Article detailsHistorical record
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The company's pipeline is delivering some milestones, but sustained high R&D spending and execution risks remain a focus for bearish perspectives.
- Published
- 7 Aug 2026 07:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
07Aug 2026
ArchivedPositive tone
Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the company liftโฆ
Article detailsHistorical record
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the company lifting its full year 2026 outlook. See our latest analysis for BeOne Medicines. These results sit against a share price that has gained 6.8% over the past month and 6.0% year to date, while the 3 year total shareholder return of 66.6% points to sustained investor confidence in BeOne Medicines. If BeOne Medicines
- Published
- 7 Aug 2026 01:18
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Balance SheetBiotechEarningsFuture Cash FlowsGuidanceShare Price
06Aug 2026
UBS Group has raised its target price for BeiGene (ONC.US) to $467, following the company's strong second-quarter earnings performance. The firm reiterated its "Buy" rating and named BeiGene as a top pick, citing its robust product pipeline and favorable market position. This upward revisโฆ
Article detailsHistorical record
UBS Group has raised its target price for BeiGene (ONC.US) to $467, following the company's strong second-quarter earnings performance. The firm reiterated its "Buy" rating and named BeiGene as a top pick, citing its robust product pipeline and favorable market position. This upward revision reflects confidence in BeiGene's continued financial strength and growth trajectory.
- Published
- 6 Aug 2026 08:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
06Aug 2026
ArchivedPositive tone
Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the company liftโฆ
Article detailsHistorical record
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings surpassing analyst expectations and the company lifting its full year 2026 outlook. See our latest analysis for BeOne Medicines. These results sit against a share price that has gained 6.8% over the past month and 6.0% year to date, while the 3 year total shareholder return of 66.6% points to sustained investor confidence in BeOne Medicines. If BeOne Medicines
- Published
- 6 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Balance SheetBiotechEarningsFuture Cash FlowsGuidanceShare Price
06Aug 2026
ArchivedPositive tone
Beigene Ltd (ONC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Article detailsHistorical record
- Published
- 6 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
06Aug 2026
ArchivedPositive tone
BeOne Medicines (ONC) Stock Climbs As Profit Growth Meets BRUKINSA Reliance
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The โฆ
Article detailsHistorical record
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The company's pipeline is delivering some milestones, but sustained high R&D spending and execution risks remain a focus for bearish perspectives.
- Published
- 6 Aug 2026 00:47
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
05Aug 2026
BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.71 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 29.6%. EPS of $2.05 for the same period compares to $0.84 a year ago. The reported revenue represents a surprise of +2.99% over the Zacksโฆ
Article detailsHistorical record
BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.71 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 29.6%. EPS of $2.05 for the same period compares to $0.84 a year ago. The reported revenue represents a surprise of +2.99% over the Zacks Consensus Estimate of $1.66 billion. With the consensus EPS estimate being $1.40, the EPS surprise was +46.43%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate
- Published
- 5 Aug 2026 14:30
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsRevenue
05Aug 2026
BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven primarily by strong global sales of its core product, Brukinsa. The company has also raised its full-year revenue guidance to a range of 44.9 billion to 46.2 billion yuan, refleโฆ
Article detailsHistorical record
BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven primarily by strong global sales of its core product, Brukinsa. The company has also raised its full-year revenue guidance to a range of 44.9 billion to 46.2 billion yuan, reflecting continued growth and the recent accelerated FDA approval of its new drug Sonrotoclax. This performance indicates BeiGene's transition towards increased profitability, solidifying its position in the innovative drug market.
- Published
- 5 Aug 2026 13:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
05Aug 2026
ArchivedPositive tone
BeOne Medicines (ONC) Stock Climbs As Profit Growth Meets BRUKINSA Reliance
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The โฆ
Article detailsHistorical record
BeOne Medicines (ONC) saw its stock climb after reporting strong Q2 2026 earnings, with profits significantly increasing. While the company is showing clear profitability, its reliance on the drug BRUKINSA for the majority of its revenue raises concentration concerns among investors. The company's pipeline is delivering some milestones, but sustained high R&D spending and execution risks remain a focus for bearish perspectives.
- Published
- 5 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
03Aug 2026
ArchivedLegacy ยท tone unscored
Legacy source lookup
Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $15,086,671.00 in Stock
Article detailsHistorical record
- Published
- 3 Aug 2026 17:49
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Aug 2026
ArchivedPositive tone
Beigene Ltd (ONC) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Beigene Ltd (ONC), assigning it a strong financial score of 9.13, which ranks it highly within the Biotechnology & Medical Research industry. The company demonstrated robust operating efficiency, with a significant year-over-year revenue increโฆ
Article detailsHistorical record
This article analyzes the financial health of Beigene Ltd (ONC), assigning it a strong financial score of 9.13, which ranks it highly within the Biotechnology & Medical Research industry. The company demonstrated robust operating efficiency, with a significant year-over-year revenue increase of 35.46% and a net profit increase of 17802.13% in its latest quarter. The report highlights strong performance across various financial dimensions including cash and cash equivalents, total assets, and operating profit.
- Published
- 1 Aug 2026 04:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
31Jul 2026
ArchivedPositive tone
Earnings Preview: BeiGene to Report Financial Results Pre-market on August 05
BeiGene (NASDAQ: BGNE) is scheduled to report its Q2 2026 earnings before market open on Wednesday, August 5, 2026. Analysts expect the company to post an EPS of -$3.66 and revenue of $475.29 million. Over the last year, BeiGene has experienced 3 EPS increases and 1 EPS decrease, with itsโฆ
Article detailsHistorical record
BeiGene (NASDAQ: BGNE) is scheduled to report its Q2 2026 earnings before market open on Wednesday, August 5, 2026. Analysts expect the company to post an EPS of -$3.66 and revenue of $475.29 million. Over the last year, BeiGene has experienced 3 EPS increases and 1 EPS decrease, with its share price rising 40.56%.
- Published
- 31 Jul 2026 15:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
31Jul 2026
This article provides a technical analysis of Beigene Ltd (ONC), detailing its current price momentum score, support and resistance levels, and various technical indicator readings. It shows that the stock is currently suitable for range-bound swing trading, with a neutral signal based onโฆ
Article detailsHistorical record
This article provides a technical analysis of Beigene Ltd (ONC), detailing its current price momentum score, support and resistance levels, and various technical indicator readings. It shows that the stock is currently suitable for range-bound swing trading, with a neutral signal based on moving averages and other technical indicators. The analysis also includes FAQs explaining technical ratings and moving averages.
- Published
- 31 Jul 2026 03:40
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
30Jul 2026
ArchivedNeutral tone
Beigene Ltd (ONC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Beigene Ltd (ONC), noting its current valuation score is 5.88 and it ranks 355 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 67.69, which is significantly below its recent high but above its reโฆ
Article detailsHistorical record
This article provides a valuation analysis for Beigene Ltd (ONC), noting its current valuation score is 5.88 and it ranks 355 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 67.69, which is significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company.
- Published
- 30 Jul 2026 15:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
EarningsFinancial MarketsLife Sciences
28Jul 2026
ArchivedNeutral tone
Beigene Ltd (ONC) Institutional Confidence
This article analyzes the institutional confidence in Beigene Ltd (ONC), noting its current institutional shareholding score of 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion has increased by 17.61% quarter-over-quarter, with ETHSX being the largesโฆ
Article detailsHistorical record
This article analyzes the institutional confidence in Beigene Ltd (ONC), noting its current institutional shareholding score of 3.00, ranking 192 out of 386 in its industry. The institutional shareholding proportion has increased by 17.61% quarter-over-quarter, with ETHSX being the largest shareholder. The article lists major institutional shareholders and their recent activity.
- Published
- 28 Jul 2026 04:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
28Jul 2026
ArchivedNeutral tone
Beigene Ltd (ONC) Income Statement
This article provides the quarterly and annual income statements for Beigene Ltd (ONC), offering detailed financial data such as total revenue, operating expenses, and net income over several years. It includes key financial metrics and a FAQ section explaining how to interpret the incomeโฆ
Article detailsHistorical record
This article provides the quarterly and annual income statements for Beigene Ltd (ONC), offering detailed financial data such as total revenue, operating expenses, and net income over several years. It includes key financial metrics and a FAQ section explaining how to interpret the income statement and defining terms like YOY (year over year).
- Published
- 28 Jul 2026 02:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
27Jul 2026
ArchivedNeutral tone
Beigene Ltd (ONC) Cash Flow
This article provides Beigene Ltd's (ONC) cash flow statement, offering detailed quarterly and annual data for operating, investing, and financing activities. It includes key figures such as net income from continuing operations, capital expenditures, and free cash flow over several yearsโฆ
Article detailsHistorical record
This article provides Beigene Ltd's (ONC) cash flow statement, offering detailed quarterly and annual data for operating, investing, and financing activities. It includes key figures such as net income from continuing operations, capital expenditures, and free cash flow over several years. The report also defines and explains the significance of various cash flow components for evaluating the company's financial health.
- Published
- 27 Jul 2026 14:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
27Jul 2026
ArchivedNeutral tone
Beigene Ltd (ONC) Balance Sheet
This article provides Beigene Ltd's (ONC) balance sheet data, including quarterly and annual figures for assets, liabilities, and shareholders' equity. It details various financial metrics such as cash and short-term investments, receivables, inventory, current and non-current assets, andโฆ
Article detailsHistorical record
This article provides Beigene Ltd's (ONC) balance sheet data, including quarterly and annual figures for assets, liabilities, and shareholders' equity. It details various financial metrics such as cash and short-term investments, receivables, inventory, current and non-current assets, and different categories of liabilities. The content allows for evaluation of the company's financial health, fundamental analysis, and calculation of key ratios.
- Published
- 27 Jul 2026 14:05
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
27Jul 2026
ArchivedNeutral tone
Beigene Ltd (ONC) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Beigene Ltd (ONC), noting its current valuation score is 5.88 and it ranks 355 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 67.69, which is significantly below its recent high but above its reโฆ
Article detailsHistorical record
This article provides a valuation analysis for Beigene Ltd (ONC), noting its current valuation score is 5.88 and it ranks 355 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 67.69, which is significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company.
- Published
- 27 Jul 2026 08:45
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
27Jul 2026
ArchivedNeutral tone
Beigene Ltd (ONC) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Beigene Ltd's (ONC) dividend and stock split history. It notes that the company has distributed a total of $0.00 USD in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock performance data incโฆ
Article detailsHistorical record
This article provides an overview of Beigene Ltd's (ONC) dividend and stock split history. It notes that the company has distributed a total of $0.00 USD in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock performance data including its market cap and P/E ratio.
- Published
- 27 Jul 2026 02:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
27Jul 2026
This article provides a detailed revenue breakdown for Beigene Ltd (ONC), presenting data by business segment and geographical region. It shows that in FY2025Q3, products accounted for 97.35% of revenue, with BRUKINSA being the top contributor. Geographically, the United States accounted โฆ
Article detailsHistorical record
This article provides a detailed revenue breakdown for Beigene Ltd (ONC), presenting data by business segment and geographical region. It shows that in FY2025Q3, products accounted for 97.35% of revenue, with BRUKINSA being the top contributor. Geographically, the United States accounted for the largest share of revenue, followed by China and Europe.
- Published
- 27 Jul 2026 02:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
23Jul 2026
ArchivedNeutral tone
BeiGene(ONC.US) Officer Sells US$34.59 Million in Common Stock
An officer at BeiGene (ONC.US) recently sold a significant amount of common stock, totaling US$34.59 million. This transaction indicates a notable insider sale activity at the company.
Article detailsHistorical record
An officer at BeiGene (ONC.US) recently sold a significant amount of common stock, totaling US$34.59 million. This transaction indicates a notable insider sale activity at the company.
- Published
- 23 Jul 2026 01:40
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceFinancial Markets
22Jul 2026
ArchivedLegacy ยท tone unscored
Legacy source lookup
ONC Stock Price and Chart โ NASDAQ:ONC
Article detailsHistorical record
- Published
- 22 Jul 2026 02:15
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
20Jul 2026
ArchivedPositive tone
BeiGene stock steadies as oncology revenue grows and losses narrow
BeiGene Ltd. reported strong oncology revenue growth in 2023, exceeding $2.1 billion, driven by product sales of key therapies like Brukinsa and tislelizumab. The Nasdaq-listed biotech company also managed to narrow its net loss despite significant ongoing investment in research and develโฆ
Article detailsHistorical record
BeiGene Ltd. reported strong oncology revenue growth in 2023, exceeding $2.1 billion, driven by product sales of key therapies like Brukinsa and tislelizumab. The Nasdaq-listed biotech company also managed to narrow its net loss despite significant ongoing investment in research and development and global commercial expansion. This performance highlights the company's transition towards a more diversified global commercial footprint and its focus on an innovation-driven oncology platform.
- Published
- 20 Jul 2026 20:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
18Jul 2026
ArchivedLegacy ยท tone unscored
Legacy source lookup
BeOne Medicines (NASDAQ:ONC) Upgraded by Wall Street Zen to "Strong-Buy" Rating
Article detailsHistorical record
- Published
- 18 Jul 2026 08:22
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
17Jul 2026
ArchivedPositive tone
Barclays Maintains BeiGene(ONC.US) With Buy Rating, Cuts Target Price to $403
Barclays has reiterated its Buy rating for BeiGene (ONC.US) but has reduced its price target from $420 to $403. This adjustment reflects a continued positive outlook on the company despite the lowered target price.
Article detailsHistorical record
Barclays has reiterated its Buy rating for BeiGene (ONC.US) but has reduced its price target from $420 to $403. This adjustment reflects a continued positive outlook on the company despite the lowered target price.
- Published
- 17 Jul 2026 03:09
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
13Jul 2026
ArchivedLegacy ยท tone unscored
Legacy source lookup
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 664 Shares of Stock
Article detailsHistorical record
- Published
- 13 Jul 2026 02:41
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
06Jul 2026
ArchivedLegacy ยท tone unscored
Legacy source lookup
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC)
Article detailsHistorical record
- Published
- 6 Jul 2026 15:43
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
04Jul 2026
ArchivedLegacy ยท tone unscored
Legacy source lookup
Wolfe Research Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $340
Article detailsHistorical record
- Published
- 4 Jul 2026 18:30
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
25Jun 2026
ArchivedLegacy ยท tone unscored
Legacy source lookup
ONC affiliate files to sell 1,068 ADS under registered plan (NASDAQ: ONC)
Article detailsHistorical record
- Published
- 25 Jun 2026 09:17
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to ONC, but the headline and available text are not mainly about BeiGene, Ltd.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ONC sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.